Skip to main content
. 2015 Jul 22;6(29):28440–28452. doi: 10.18632/oncotarget.4955

Figure 4. ATAD2 is a prognostic marker in subgroups of endometrial cancer.

Figure 4

High expression of ATAD2 identifies patients with poorer survival within the ERα positive subgroup A., the ERα-negative subgroup B. and also in the endometrioid only subgroup C.. Number in brackets represents number of disease specific deaths in each group.